Vijay Ramakrishnan, Ph.D.

President and CEO, Founder

Dr. Ramakrishnan has sixteen years of experience in biotechnology entrepreneurship. In the past three years he designed and developed KLĀRITOS' proprietary managed care model.  He is the inventor of several patents necessary to build this platform including precision medicine, therapeutic guidance, patient selection, treatment selection, and payer approvals of specialty drugs. He has been specializing in stratified medicine for the past twelve years. He founded a stratified medicine company with a goal of developing customized antibody immunotherapies tailored to specific patient subsets to achieve excellent response rates in treated patients.  Earlier, for nine years, he investigated protein biochemistry and biophysics of metalloproteins of hyperthermophiles isolated from deep-sea volcanic vents. He holds a Ph.D. in Microbiology from the University of Georgia where he was a Rotary International Foundation Scholar, and was a Post Doctoral Scholar at Caltech.

Edwin P. Ching, J.D., Ph.D.

Vice President, Chief Patent Counsel

A founding member of the team, Dr. Ching has six years of patent prosecution experience in the stratified medicine space. He has over 30 years of experience in intellectual property law at both public and private biotechnology companies. He started his legal career as an associate at Townsend & Townsend where he represented university and biotechnology company clients. He was Patent Counsel at Berlex Biosciences, the biotechnology arm of Schering, A.G., Chief Counsel at DNAX Research Institute, an immunology research institute for the Schering-Plough Corp ($41 B merger with Merck), and Vice President of Intellectual Property at Eos Biotechnology Inc. (acquired by Protein Design Labs). He has performed IP due diligence for strategic partnership and M&A transactions. He developed and executed patent strategies by preparing and prosecuting worldwide portfolios in the areas of genomics, molecular biology, and immunology covering drug discovery and technology platforms, and biologic therapies. He has a J.D. from Columbia University Law School. He has earned an A.B. in Biophysics from UC Berkeley, a Ph.D. in Biochemistry and Neurobiology from California Institute of Technology, and was a postdoctoral fellow at Rockefeller University.

John S. Russell, M.S.

Vice President, Payers & Managed Markets

A founding member of the team, Mr. Russell has thirty years biopharma industry experience including at Otsuka Pharmaceuticals, and Eli Lilly. He has significant experience in developing pricing, reimbursement, and market access strategies for approved therapies particularly oncology drugs, rare disease therapies, and other specialty drugs. As the Vice President of Managed Markets at Otsuka, his team developed the global launch pricing and reimbursement strategy for the anti-psychotic drug Abilify®, which had net sales of $6 B in the U.S in 2013. He has built and led multi-functional teams in new product planning, global market access, sales, and business planning. During his career, he was responsible for or contributed to the launch of ten new products spanning thirteen different therapeutic classes.


David B. Snow, Jr.

Ex-Chairman and CEO, MEDCO Health Solutions

Thomas A. Scully, J.D.

Ex-Administrator, Centers for Medicare & Medicaid Services

Gail R. Wilensky, Ph.D.

Ex-Administrator, Centers for Medicare & Medicaid Services

Vern Norviel, J.D.

Partner, Wilson Sonsini Goodrich & Rosati

Jack Lewin, M.D.

Chairman, National Coalition on Health Care

David R. Fiorentino, M.D., Ph.D.

Stanford University, Professor of Dermatology, Immunology & Rheumatology